JP2018530623A - ドキソルビシンおよびマイトマイシンｃプロドラッグを共封入したリポソーム組成物 - Google Patents

ドキソルビシンおよびマイトマイシンｃプロドラッグを共封入したリポソーム組成物 Download PDF

Info

Publication number
JP2018530623A
JP2018530623A JP2018539238A JP2018539238A JP2018530623A JP 2018530623 A JP2018530623 A JP 2018530623A JP 2018539238 A JP2018539238 A JP 2018539238A JP 2018539238 A JP2018539238 A JP 2018539238A JP 2018530623 A JP2018530623 A JP 2018530623A
Authority
JP
Japan
Prior art keywords
mitomycin
doxorubicin
liposomes
prodrug
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018539238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530623A5 (enExample
Inventor
アルベルト・ガビゾン
パトリシア・オハナ
ヒラリー・シュミーダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patricia Ohana
Shaare Zedek Scientific Ltd
Lipomedix Pharmaceuticals Ltd
Original Assignee
Patricia Ohana
Shaare Zedek Scientific Ltd
Lipomedix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patricia Ohana, Shaare Zedek Scientific Ltd, Lipomedix Pharmaceuticals Ltd filed Critical Patricia Ohana
Publication of JP2018530623A publication Critical patent/JP2018530623A/ja
Publication of JP2018530623A5 publication Critical patent/JP2018530623A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018539238A 2015-10-15 2016-10-14 ドキソルビシンおよびマイトマイシンｃプロドラッグを共封入したリポソーム組成物 Pending JP2018530623A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242097P 2015-10-15 2015-10-15
US62/242,097 2015-10-15
PCT/US2016/057176 WO2017066667A1 (en) 2015-10-15 2016-10-14 Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c

Publications (2)

Publication Number Publication Date
JP2018530623A true JP2018530623A (ja) 2018-10-18
JP2018530623A5 JP2018530623A5 (enExample) 2019-11-14

Family

ID=57209906

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018539238A Pending JP2018530623A (ja) 2015-10-15 2016-10-14 ドキソルビシンおよびマイトマイシンｃプロドラッグを共封入したリポソーム組成物

Country Status (6)

Country Link
US (1) US10617672B2 (enExample)
EP (1) EP3362099A1 (enExample)
JP (1) JP2018530623A (enExample)
AU (1) AU2016337370A1 (enExample)
CA (1) CA3001699A1 (enExample)
WO (1) WO2017066667A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021225113A1 (ja) * 2020-05-08 2021-11-11 国立大学法人京都工芸繊維大学 イオン性化学種濃縮方法
JP2022517352A (ja) * 2019-01-11 2022-03-08 リポメディックス・ファーマシューティカルズ・リミテッド マイトマイシンｃのリポソーム化プロドラッグを含むリポソーム組成物および製造法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3001699A1 (en) 2015-10-15 2017-04-20 Lipomedix Pharmaceuticals Ltd. Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c
US20220073638A1 (en) * 2018-09-19 2022-03-10 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
CN109260155B (zh) * 2018-11-05 2021-04-06 杭州高田生物医药有限公司 伊立替康脂质体制剂及其制备与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502323A (ja) * 2003-04-30 2007-02-08 アルザ・コーポレーシヨン チオール開裂し得るマイトマイシンコンジュゲート
CN103622912A (zh) * 2013-12-05 2014-03-12 常州金远药业制造有限公司 盐酸多柔比星-多西他赛或紫杉醇脂质体制剂及其制备方法
US20140328899A1 (en) * 2011-07-13 2014-11-06 Shaare Zedek Medical Center Liposomes co-encapsulating a bisphosphonate and an amphipathic agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US20050129753A1 (en) 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
EP2531175A2 (en) 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
AU2012284147A1 (en) * 2011-07-19 2014-02-27 Stc. Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
EP2776013B8 (en) * 2011-11-08 2023-08-30 The Board of Trustees of the University of Arkansas Methods and compositions for x-ray induced release from ph sensitive liposomes
US9937261B2 (en) 2014-06-09 2018-04-10 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy
CA3001699A1 (en) 2015-10-15 2017-04-20 Lipomedix Pharmaceuticals Ltd. Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502323A (ja) * 2003-04-30 2007-02-08 アルザ・コーポレーシヨン チオール開裂し得るマイトマイシンコンジュゲート
US20140328899A1 (en) * 2011-07-13 2014-11-06 Shaare Zedek Medical Center Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
CN103622912A (zh) * 2013-12-05 2014-03-12 常州金远药业制造有限公司 盐酸多柔比星-多西他赛或紫杉醇脂质体制剂及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GABIZON A A: "REDUCED TOXICITY AND SUPERIOR THERAPEUTIC ACTIVITY OF A MITOMYCIN C LIPID-BASED PRODRUG 以下備考", CLINICAL CANCER RESEARCH, vol. VOL:12, NR:6, JPN5018006994, 15 March 2006 (2006-03-15), pages 1913 - 1920, ISSN: 0004485672 *
PREETHY PRASAD: "DOXORUBICIN AND MITOMYCIN C CO-LOADED POLYMER-LIPID HYBRID NANOPARTICLES INHIBIT GROWTH 以下備考", CANCER LETTERS, vol. VOL:334, NR:2, JPN5018006990, 1 July 2013 (2013-07-01), pages 263 - 273, ISSN: 0004485671 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022517352A (ja) * 2019-01-11 2022-03-08 リポメディックス・ファーマシューティカルズ・リミテッド マイトマイシンｃのリポソーム化プロドラッグを含むリポソーム組成物および製造法
US12171746B2 (en) 2019-01-11 2024-12-24 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
WO2021225113A1 (ja) * 2020-05-08 2021-11-11 国立大学法人京都工芸繊維大学 イオン性化学種濃縮方法
JPWO2021225113A1 (enExample) * 2020-05-08 2021-11-11

Also Published As

Publication number Publication date
US20180296529A1 (en) 2018-10-18
WO2017066667A1 (en) 2017-04-20
CA3001699A1 (en) 2017-04-20
AU2016337370A1 (en) 2018-05-17
US10617672B2 (en) 2020-04-14
EP3362099A1 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
KR101817491B1 (ko) 나노입자-기반 종양-표적 약물 전달
ES2609388T3 (es) Tratamiento del cáncer de mama triple negativo a receptores
ES2762224T3 (es) Liposomas que comprenden lípidos conjugados con polímero y usos relacionados
Bajelan et al. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance
JP2006248978A (ja) 新規なリポソーム製剤
CN104582732A (zh) 治疗癌症的组合物及其制造方法
Liu et al. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent
JP2023538133A (ja) がん治療のための複数の切断可能なプロドラッグを含むナノ粒子
RS20080388A (sr) Lečenje malignih bolesti
JP2018530623A (ja) ドキソルビシンおよびマイトマイシンｃプロドラッグを共封入したリポソーム組成物
KR20110056042A (ko) 종양세포 표적지향을 위한 나노 입자 및 이의 제조방법
CN115605196A (zh) 用于治疗癌症和癌症耐药性的脂质体制剂
EP4178543A1 (en) Liposome formulations
Orthmann et al. Improved treatment of MT-3 breast cancer and brain metastases in a mouse xenograft by LRP-targeted oxaliplatin liposomes
ES2897983T3 (es) Liposomas cargados con IPA-3 y procedimientos de uso de los mismos
ES2902576T3 (es) Tratamiento de cáncer de mama usando una combinación de una formulación liposomal catiónica de taxano, una formulación no liposomal de taxano y un agente activo adicional
US20240269318A1 (en) Nano-delivery systems comprising modified lipids and use thereof
US10925831B2 (en) Liposomal formulations of platinum-acridine anticancer agents and methods thereof
JP2022517352A (ja) マイトマイシンｃのリポソーム化プロドラッグを含むリポソーム組成物および製造法
WO2025184543A1 (en) Compositions and methods for delivery of therapeutic compounds
ES2390147B1 (es) Nanoliposomas funcionalizados con péptidos bioactivos como sistemas para mejorar la citotoxicidad de fármacos antitumorales.
US20220118116A1 (en) Adhesive/adsorption switch on nanoparticles to increase tumor uptake and delay tumor clearance
EP3960852A1 (en) Peptides for the treatment of cancer
HK40086650A (zh) 用於治疗癌症和癌症耐药性的脂质体制剂
KR20110122682A (ko) 콜레스탄올 유도체의 병용 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191007

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210413